Quantbot Technologies LP Acquires Shares of 18,849 Twist Bioscience Corporation $TWST

Quantbot Technologies LP bought a new position in Twist Bioscience Corporation (NASDAQ:TWST) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 18,849 shares of the company’s stock, valued at approximately $1,939,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC lifted its stake in Twist Bioscience by 24.4% in the second quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock valued at $97,000 after purchasing an additional 185 shares during the last quarter. Stifel Financial Corp boosted its stake in Twist Bioscience by 3.6% in the 4th quarter. Stifel Financial Corp now owns 7,769 shares of the company’s stock worth $246,000 after purchasing an additional 271 shares during the period. D.A. Davidson & CO. boosted its position in shares of Twist Bioscience by 1.2% in the fourth quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock valued at $801,000 after acquiring an additional 305 shares during the period. CWM LLC boosted its holdings in Twist Bioscience by 9.4% in the 4th quarter. CWM LLC now owns 4,738 shares of the company’s stock valued at $150,000 after purchasing an additional 407 shares during the period. Finally, California State Teachers Retirement System boosted its stake in Twist Bioscience by 0.8% during the second quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock valued at $1,994,000 after buying an additional 442 shares during the period.

Twist Bioscience Trading Down 3.3%

Shares of NASDAQ:TWST opened at $140.80 on Tuesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. The stock has a market capitalization of $8.83 billion, a price-to-earnings ratio of -63.42 and a beta of 2.14. The stock’s 50-day simple moving average is $101.89 and its two-hundred day simple moving average is $71.16. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $145.93.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The company had revenue of $118.38 million for the quarter, compared to the consensus estimate of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The business’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.33 EPS. Analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Insider Transactions at Twist Bioscience

In other news, CEO Emily M. Leproust sold 113,318 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $125.16, for a total transaction of $14,182,880.88. Following the sale, the chief executive officer directly owned 818,938 shares of the company’s stock, valued at $102,498,280.08. This represents a 12.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Adam Laponis sold 2,399 shares of the company’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $94.33, for a total transaction of $226,297.67. Following the sale, the chief financial officer directly owned 110,276 shares in the company, valued at approximately $10,402,335.08. The trade was a 2.13% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 151,529 shares of company stock valued at $17,708,772. 3.08% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research analysts recently issued reports on TWST shares. TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 3rd. Leerink Partners set a $110.00 target price on shares of Twist Bioscience in a report on Thursday, July 16th. Guggenheim restated a “buy” rating on shares of Twist Bioscience in a report on Monday. Barclays boosted their price objective on shares of Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a research report on Wednesday, June 24th. Finally, Piper Sandler increased their target price on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.30.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.